VolitionRx Limited (NYSE American: VNRX) is drawing attention to a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter to highlight the test's potential.
Multiple studies have demonstrated that the Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. Volition noted that most of the supporting research has been peer reviewed and published, with experts observing consistent findings across various countries and patient populations.
The company believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. For more details, the full press release is available at https://ibn.fm/2IH3m.
Volition is a multinational company focused on advancing epigenetics. Through its subsidiaries, it develops and commercializes simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
This announcement underscores the potential of the Nu.Q NETs test to improve sepsis management, a critical area given that sepsis is a leading cause of death worldwide. The ability to accurately diagnose and prognosticate sepsis could lead to earlier interventions and better patient outcomes.
